Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.75 |
| ▸ | MEN1 | O00255 | 3/20 | 0.75 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12325797 | 0.81 | MEN1 (0.52) | KMT2AMEN1POLBKDM4EHSD17B10 | |
| SCHEMBL541947 | 0.73 | MEN1 (0.49) | KMT2AMEN1POLBKDM4EHSD17B10 | |
| SCHEMBL30209785 | 0.73 | MEN1 (0.49) | KMT2AMEN1POLBKDM4EHSD17B10 | |
| SCHEMBL17822118 | 0.71 | MEN1 (0.43) | KMT2AMEN1POLBKDM4EHSD17B10 | |
| SCHEMBL5624732 | 0.71 | MEN1 (0.77) | KMT2AMEN1POLBKDM4EHSD17B10 | |
| SCHEMBL18324078 | 0.68 | TNKS2 (0.52) | KMT2AMEN1POLBKDM4EHSD17B10 | |
| SCHEMBL24566501 | 0.68 | KDM4E (0.42) | KMT2AMEN1POLBKDM4EHSD17B10 | |
| SCHEMBL5981976 | 0.68 | MEN1 (0.45) | KMT2AMEN1POLBKDM4EHSD17B10 | |
| SCHEMBL23605864 | 0.66 | MEN1 (0.38) | KMT2AMEN1HSD17B10ALDH1A1HPGD | |
| SCHEMBL26323299 | 0.65 | KMT2A (0.42) | KMT2AMEN1POLBKDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306611-A1 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110230523-A1 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | PARATEK PHARMACEUTICALS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20090131401-A1 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131401-A1 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-7405235-B2 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-7405235-B2 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| WO-2004041209-A2 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | PARATEK PHARMACEUTICALS, INC. (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306611-A1 | Transcription factor modulating compounds and methods of use thereof | JUN, CREBBP, TFEB | KMT2A 806/4885MEN1 4225/4885POLB 679/4885 |
| US-20090131401-A1 | Transcription factor modulating compounds and methods of use thereof | JUN, CREBBP, TFEB | KMT2A 806/4885MEN1 4225/4885POLB 679/4885 |
| US-20110230523-A1 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | JUN, CREBBP, TFEB | KMT2A 806/4885MEN1 4225/4885POLB 679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.